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	 	Are	topical	nitrates	safe	and	
effective	for	upper	extremity		
tendinopathies?	
	 Topical	nitrates	provide	short-	
	 term	relief	with	some	side	effects,	
especially	 headache.	 Topical	 nitroglycerin	
(NTG)	 patches	 improve	 subjective	 pain	
scores	by	about	30%	and	 range	of	motion	
over	 3	 days	 in	 patients	 with	 acute	 shoul-
der	 tendinopathy	 (strength	 of	 recom-
mendation	 [SOR]:	 C,	 small	 randomized	
controlled	trial	[RCT]	with	no	methodologic	
flaws).
NTG	 patches,	 when	 combined	 with	
tendon	 rehabilitation,	 improve	 subjec-
tive	pain	 ratings	by	about	30%	and	shoul-
der	strength	by	about	10%	in	patients	with	
chronic	 shoulder	 tendinopathy	 over	 3	 to	
6	months,	 but	not	 in	 the	 long	 term	 (SOR:	
C,	 RCTs	 with	 methodologic	 flaws).	 They	
improve	pain	and	strength	15%	to	50%	for	
chronic	 extensor	 tendinosis	 of	 the	 elbow	
over	a	6-month	period	(SOR:	C,	small	RCT	
with	methodologic	flaws).
NTG	patches	used	without	tendon	re-
habilitation	don’t	improve	pain	or	strength	
in	chronic	lateral	epicondylitis	over	8	weeks	
(SOR:	C,	RCT).
Topical	NTG	 patches	 commonly	 pro-
duce	headaches	and	rashes	(SOR:	B,	mul-
tiple	RCTs).
Evidence summary
A	 small	 RCT	 found	 that	 NTG	 therapy	 im-
proved	 short-term	 pain	 and	 joint	 mobility	
in	 patients	 with	 acute	 supraspinatus	 tendi-
nitis.1	 Investigators	randomized	10	men	and	
10	 women	 with	 acute	 shoulder	 tendonitis	
(fewer	 than	 7	 days’	 duration)	 to	 use	 either	
5-mg	NTG	patches	or	placebo	patches	daily	
for	3	days.	Patients	 rated	pain	on	a	10-point	
scale,	 and	 investigators	measured	 joint	mo-
bility	on	a	4-point	scale.	
After	48	hours	of	treatment,	NTG	patches	
significantly	reduced	pain	ratings	from	base-
line	(from	7	to	2	points;	P<.001),	whereas	pla-
cebo	didn’t	(6	vs	6	points;	P	not	significant).	
NTG	 patches	 also	 improved	 joint	 mobility	
from	baseline	(from	2	points	“moderately	re-
stricted”	to	.1	points	“not	restricted”;	P<.001),	
but	 placebo	 didn’t	 (1.2	 points	 “mildly	 re-
stricted”	 vs	 1.2	 points;	 P	 not	 significant).	
The	 placebo	 group	 had	 less	 pain	 and	 joint	
restriction	than	the	NTG	group	at	the	start	of	
the	 study.	 Two	 patients	 reported	 headache	
24	hours	after	starting	treatment.
NtG plus rehabilitation improves  
chronic shoulder pain, range of motion
A	double-blind	RCT	evaluating	NTG	patches	
for	 53	 patients	 (57	 shoulders)	 with	 chronic	
supraspinatus	 tendinopathy	 (shoulder	 pain	
lasting	 longer	 than	 3	 months)	 found	 that	
they	 improved	 pain,	 strength,	 and	 range	 of	
motion	at	3	 to	6	months.2	 Investigators	ran-
domized	 patients	 to	 receive	 one-quarter	 of	
a	5-mg	24-hour	NTG	patch	or	placebo	patch	
daily	and	enrolled	all	patients	in	a	rehabilita-
tion	program.	They	assessed	subjective	pain	
(at	night	and	with	activity),	strength,	and	ex-
ternal	rotation	at	baseline	and	at	2,	6,	12,	and	
24	weeks.	
NTG	 patches	 improved	 nighttime	 pain	
about	 30%	 (at	 12	 and	 24	 weeks),	 pain	 with	
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activity	 about	 60%	 (at	 24	 weeks),	 strength	
about	 10%	 (at	 12	 and	 24	weeks),	 and	 range	
of	motion	about	20%	(at	24	weeks;	P<.05	for	
all	comparisons).	The	placebo	group	initially	
had	more	pain,	less	strength,	and	less	mobili-
ty	than	the	NTG	group.	Investigators	reported	
no	adverse	effects.
NtG and rehab improve elbow pain,  
but with side effects
Another	RCT	comparing	topical	NTG	patch-
es	 in	 patients	 with	 chronic	 extensor	 tendi-
nosis	of	the	elbow	found	that	they	improved	
most	 parameters.3	 Investigators	 randomized	
86	 patients	 with	 elbow	 tendonitis	 (longer	
than	3	months)	to	NTG	patches	(one-quarter	
of	a	5-mg	24-hour	patch)	or	placebo	patches	
and	 enrolled	 all	 patients	 in	 a	 tendon	 reha-
bilitation	program.	They	assessed	subjective	
pain,	extensor	tendon	tenderness,	and	mus-
cle	 strength	 at	 baseline	 and	 at	 2,	 6,	 12,	 and	
24	weeks.	
NTG	patches	 improved	subjective	pain,	
tendon	tenderness,	and	strength	significantly	
more	than	placebo	at	all	follow-up	points,	by	
15%	to	50%	(P<.05	for	all	comparisons).	The	
study	was	flawed	because	 the	control	group	
started	 with	 more	 pain,	 tenderness,	 and	
weakness	than	the	NTG	group.	Five	patients	
discontinued	NTG	because	of	adverse	effects	
(headache,	dermatitis,	and	facial	flushing).
z A follow-up study done 5 years af-
ter discontinuation of therapy	found	equal	
outcomes	with	NTG	and	placebo.4	Investiga-
tors	evaluated,	by	phone	or	 in	person,	58	of	
the	86	patients	in	the	original	study.	NTG	and	
placebo	therapy	produced	equivalent	reduc-
tions	 in	 subjective	 0	 to	 4	 elbow	pain	 scores	
over	baseline	(average	pain	2.5	initially,	1.5	at	
12	weeks,	and	1.0	at	5	years;	P<.01	for	all	com-
parisons	with	baseline,	no	significant	differ-
ence	between	nitrates	and	placebo).	
NtG without rehab works no better 
than placebo
Another	RCT	that	evaluated	3	different	doses	
of	NTG	 patches	 for	 8	weeks	 in	 154	 patients	
with	chronic	lateral	epicondylosis	found	NTG	
treatment	was	no	better	than	placebo	for	pain	
or	 strength.5	 Investigators	 randomized	 pa-
tients	with	more	than	3	months	of	symptoms	to	
3	 NTG	 patch	 doses	 (.72	mg/24	 h,	 1.44	mg/	
24	 h,	 or	 3.6	 mg/24	 h)	 compared	 with	 pla-
cebo	 and	 evaluated	 subjective	 pain	 (at	 rest,	
with	activity,	and	at	night),	grip	strength,	and	
force,	at	baseline	and	8	weeks.	
The	study	lacked	a	formal	wrist	strength-
ening	rehabilitation	program.	Patients	in	the	
placebo	group	had	lower	baseline	pain	scores	
than	the	NTG	groups.	Seven	patients	dropped	
out	of	the	study	because	of	headaches.
Recommendations
We	found	no	authoritative	recommendations	
regarding	the	use	of	topical	nitrates	for	upper	
extremity	tendinopathies.	
An	 online	 reference	 text	 doesn’t	make	 a	
recommendation,	 but	 references	 the	 studies	
described	 previously.6 The	 authors	 state	 that	
headache	is	the	most	common	adverse	effect	
of	 topical	 nitrates,	 but	 it	 becomes	 less	 severe	
over	the	course	of	treatment.	They	recommend	
caution	in	patients	with	hypotension,	pregnan-
cy,	or	migraines,	and	those	who	take	diuretics.	
The	authors	also	note	that	nitrates	are	relatively	
contraindicated	in	patients	with	ischemic	heart	
disease,	 anemia,	 phosphodiesterase	 inhibi-
tor	 therapy	 (such	as	 sildenafil),	 angle-closure	
glaucoma,	and	allergy	to	nitrates.					 														JFP
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